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Abstract. The detection of prostate cancer (PCa) biomarkers in 
bodily fluids, a process known as liquid biopsy, is a promising 
approach and particularly beneficial when performed in urine 
samples due to their maximal non‑invasiveness requirement of 
collection. A number of gene panels proposed for this purpose 
have allowed discrimination between disease‑free prostate 
and PCa; however, they bear no significant prognostic value. 
With the purpose to develop a gene panel for PCa diagnosis 
and prognosis, the methylation status of 17 cancer‑associated 
genes were analyzed in urine cell‑free DNA obtained 
from 31 patients with PCa and 33 control individuals using 
methylation‑specific polymerase chain reaction (MSP). 
Among these, 13 genes indicated the increase in methylation 
frequency in patients with PCa compared with controls. No 
prior association has been reported between adenomatosis 
polyposis coli 2 (APC2), homeobox A9, Wnt family member 
7A (WNT7A) and N‑Myc downstream‑regulated gene 4 
protein genes with PCa. The 6‑gene panel consisting of APC2, 
cadherin 1, forkhead box P1, leucine rich repeat containing 
3B, WNT7A and zinc family protein of the cerebellum 
4 was subsequently developed providing PCa detection 
with 78% sensitivity and 100% specificity. The number of 
genes methylated (NGM) value introduced for this panel 
was indicated to rise monotonically from 0.27 in control 
individuals to 4.6 and 4.25 in patients with highly developed 
and metastatic T2/T3 stage cancer, respectively. Therefore, the 
approach of defining the NGM value may not only allow for 
the detection of PCa, but also provide a rough evaluation of 
tumor malignancy and metastatic potential by non‑invasive 
MSP analysis of urine samples.
Introduction
According to the most recent global estimates in 2012, ~307,000 
and ~3,000 prostate cancer (PCa)‑associated mortalities were 
reported globally and in Ukraine, respectively, and 1,111,700 
and ~7,000 novel cases were diagnosed, respectively (1,2). 
Although the advent of relatively non‑invasive prostate‑specific 
antigen (PSA) testing has notably improved PCa diagnosis, 
its routine usage remains controversial, since a false positive 
diagnosis rate of PCa, over‑treatment, and excessive medical 
spending has been reported (3‑5). It has been reported that up 
to 75% of patients with elevated PSA level (>4 ng/µl) do not 
have any prostatic malignancy, although at least 1/3 of afore‑
mentioned patients undergo subsequent invasive follow‑up 
evaluation, including prostate biopsy (6). Additionally, ~25% 
of individuals with normal PSA level exhibit biopsy evidence 
for PCa (7,8). Another important limitation of a canonical 
PSA assay is that it is neither a reliable discriminator between 
prostatic cancer and benign hyperplasia nor a precise staging 
indicator of PCa (4,5). Therefore, the development of an 
accurate, discriminative, and cost‑efficient non‑invasive PCa 
diagnostic tool is required.
Previous studies involving high‑throughput techniques, 
including genome‑wide sequencing, failed to identify a 
common genetic driver event (e.g. specific point mutation) in 
PCa tumorigenesis (9,10). None of the recurrent mutations have 
been reported to appear in 40‑50% of PCa cases, including 
transmembrane serine protease 2‑ERG fusion and phospha‑
tase and tensin homolog (PTEN) deletion (10). Additionally, 
when examined for alterations in DNA sequences, PCa 
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demonstrates comparatively high clonal heterogeneity or even 
distinct genomic origin, complicating the use of mutation 
hotspots as tumor biomarkers (11). Instead it has been indicated 
that epigenetic alterations, including cytosine base followed 
immediately by a guanine base island methylation, occur in a 
number of loci in 80‑90% of PCa cases, including methylation 
of glutathione S‑transferase π 1 (GSTP1) gene promoter, may 
drive the neoplastic transformation and would be a preferable 
target for prostate cancer diagnosis and its biological potential 
assessment (11‑13).
It has been previously proposed that the free‑floating DNA 
fragments originating from the apoptotic/necrotic malignant 
cells in bodily fluids may be used for the detection of cancer 
biomarkers (14). This approach, also referred to as liquid 
biopsy, would be particularly beneficial when performed on 
urine samples, due to the maximal non‑invasive requirements 
for its collection, which notably improves patient's compliance 
and safety (15). Urine contains notable amounts of cell‑free 
DNA (UcfDNA) with a concentration of up to 250 ng/ml 
and consisting of the following two size category fragments: 
Long (>1 kb), which are primarily cell‑associated, including 
from the exfoliated epithelium; and short (150‑250 bp), which 
are predominantly non‑cell associated and originate from 
urogenital tract per se or circulation (16,17). This observa‑
tion potentially makes UcfDNA the optimal source of data 
for diagnosing urogenital system cancer types. The prostate, 
whose lumen is continuously connected to the urogenital tract 
via prostatic sinuses, may be the optimal organ for investiga‑
tion by means of UcfDNA analysis, which was successfully 
demonstrated by a number of studies (18‑22).
In an effort to extend the list of biomarkers applicable 
for non‑invasive PCa detection, the methylation profile of 17 
cancer‑associated genes was examined using the approach 
of UcfDNA analysis in the urine from patients with prostate 
cancer. From a functional perspective, the genes investigated in 
the present study are considered well‑established tumor suppres‑
sors from earlier reports and participate in PCa pathogenesis 
[forkhead box P1 (FOXP1), FOXP3, FOXP4, hypermethylated 
in cancer 1 (HIC1), zinc finger protein of the cerebellum 4 
(ZIC4), PTEN, cadherin 1 (CDH1), O‑6‑methylguanine‑DNA 
methyltransferase (MGMT) and leucine rich repeat containing 
3B (LRRC3B)] or are known to be associated with other malig‑
nancies [adenomatosis polyposis coli 2 (APC2), homeobox 
A9 (HOXA9), Wnt family member 7A (WNT7A) and N‑Myc 
downstream‑regulated gene 4 protein (NDRG4)] (23,24). 
The protein products of FOXP1, FOXP3, FOXP4, ZIC4 
and HOXA9 are members of three families of transcription 
factors, including Forkhead, Zic, and HOX, which are broadly 
involved in the processes of tissue morphogenesis and cell 
differentiation (13,22,25). A number of genes encode the extra‑
cellular and intracellular signaling proteins, including ligands 
(WNT7A), binding factors (APC2) and enzymes (NDRG4 and 
PTEN), are known to take part in embryonic development and 
cell cycle regulation as well (26‑28). E‑cadherin encoded by 
the CDH1 gene is a key adhesion molecule in the epithelial 
tissues crucial for the formation of adherent junctions, whose 
disruption results in tumor metastasis (29). The gene MGMT, 
which encodes the pivotal reparation enzyme MGMT, has been 
extensively implicated in the neoplastic transformation, due to 
the increased mutation rate following its silencing (29). The 
product of the LRRC3B gene is a 29‑kDa membrane‑bound 
protein, whose function, to the best of our knowledge, has yet 
to be defined; however, it has been reported to participate in the 
tumorigenesis of a number of human cancer types, including 
clear cell renal cell carcinoma (30).
In the present study this initial gene set was analyzed and 
13 genes demonstrating a statistically significant increase 
in methylation frequency in the PCa group, compared with 
controls, were selected. A final panel of 6 genes, including 
APC2, CDH1, FOXP1, LRRC3B, WNT7A, and ZIC4, was 
formed based on zero/low methylation level in controls, with 
significant moderate‑to‑strong correlation with tumor stage, 
and no significant correlation with patient's age. Within the 
panel, the number of genes methylated (NGM) was observed 
to increase monotonically from control samples to highly 
developed and metastatic types of cancer, providing a simple 
and cost‑efficient method to identify tumor stage using the 
NGM value in the urine sample.
Materials and methods
Patients sample collection. The present study was approved 
by the local Ethics Committee of the Institute of Molecular 
Biology and Genetics of the National Academy of Sciences 
of Ukraine (approval no. 18/4). Urine samples were collected 
between May and October 2017 from 64 individuals, including 
31 patients diagnosed with PCa and receiving treatment at the 
Institute of Urology NAMSU, and 33 patients who were diag‑
nosed as disease‑free controls. Patient's detailed information is 
presented in Table I. None of the patients with PCa or control 
individuals underwent radical prostatectomy or any type of 
pharmacological treatment prior to sampling. All patients 
provided written informed consent to participate in the present 
study. In each case the diagnosis was further confirmed and 
the tumor was graded according to the Gleason scoring system 
on prostate biopsy followed by histological examination (31). 
The Tumour‑node‑metastasis (TNM) staging system was 
used to classify PCa cases according to their development and 
malignancy (32). Within the cancer group, individuals were 
categorized with localized, including T1 and T2N0M0/NxM0 
(n=5 and n=9, respectively) PCa, locally‑advanced, including 
T3N0M0 (n=10) PCa, and metastatic, including T2NxM1/N1M1 
and T3N1M1 (n=3 and n=4, respectively) PCa.
UcfDNA isolation. Voided urine (50 ml) was harvested from 
patients following prostate massage on the previous day of 
definitive surgery. Each sample was spun at 3,000 x g for 
10 min at room temperature, the supernatant was removed, and 
the pellet was washed twice with 1X PBS. The resultant pellet 
was cryopreserved at ‑80˚C. Genomic DNA was extracted 
using a Quick‑gDNA MiniPrep kit (Zymo Research Corp., 
Irvine, CA, USA), according to the manufacturer's protocol. 
The quality of isolated DNA was checked by 3% agarose 
gel electrophoresis. For the DNA concentration and purity 
measurements, a spectrophotometer ND‑2000 (NanoDrop 
Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) was utilized.
Bisulfite treatment and methylation‑specific real‑time 
polymerase chain reaction (MSP). Extracted UcfDNA 
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was subjected to bisulfite conversion using an EZ DNA 
Methylation kit (Zymo Research Corp.), according to manufac‑
turer's protocol. MSP was conducted using 34 pairs of forward 
and reverse primers of methylated or unmethylated type. 
Nucleotide sequences are presented in Table II. All primers 
were designed with MethPrimer 2.0 online software (The Li 
Lab, Beijong, China; http://www.urogene.org/methprimer) and 
their performance was evaluated using 6% polyacrylamide 
gel electrophoresis. The size of the polymerase chain reaction 
products was within the range of 87‑263 bp. Each reaction 
mix contained 2.5 µl 10X DreamTaq buffer (Thermo Fisher 
Scientific, Inc.), 0.3 mM primers, 100 ng UcfDNA previously 
subjected to bisulfite conversion and nuclease‑free water to a 
final volume of 25 µl. MSP was performed using thermocy‑
cler CFX96 Real‑Time system (Bio‑Rad Laboratories, Inc., 
Hercules, CA, USA), according to the following protocol: 
Initial 12‑min incubation at 95˚C, followed by 40 cycles of 
denaturation for 15 sec at 95˚C, annealing for 30 sec at 60˚C 
and extension for 30 sec at 72˚C.
Statistical analysis. Statistical analysis was performed using 
STATISTICA 7.0 software (StatSoft, Inc., Tulsa, OK, USA). 
Since the data obtained were not normally distributed, it 
was analyzed with a non‑parametric approach. P<0.05 was 
considered to indicate a statistically significant difference. 
The comparison of PCa and control groups for the methylation 
frequency in the 17 genes was conducted with Mann‑Whitney 
U‑test. The Spearman's rank correlation coefficient with 
Bonferroni correction for multiple hypothesis testing was 
used to calculate correlation between methylation rate and 
patient's age or tumor stage. For this evaluation, the variables 
were measured on the ordinal scale. In the correlation analysis 
with regards to age, patients with PCa and controls were 
involved, while during the correlation analysis with regards 
to stage, only patients with cancer were taken into account. A 
resulting R‑value >0.3 along with P<0.05 was considered to 
indicate a positive correlation between the values examined. 
The comparison of the control and five cancer groups after 
the NGM value was calculated was performed using the 
Kruskal‑Wallis test with Conover's post‑hoc analysis adjusted 
by the Benjamini‑Hochberg false discovery rate method. The 
results are presented as the means ± standard error of the mean.
Results
Examination of the methylation status of 17 genes in PCa and 
control groups. The methylation frequency of 17 gene promoters 
was evaluated in urine samples from patients with PCa and the 
control group (Table III). The increase in methylation frequency 
in tumor samples was the lowest for FOXP2 (3.03‑6.45%) and the 
highest for ZIC4 (6.06‑58.06%) genes, compared with controls. 
Among the panel analyzed, 8 genes, including WNT7A, LRRC3B, 
FOXP3, FOXP4, CDH1, HOXA9, NDRG4 and PTEN, were not 
methylated in all of the control samples. However, aforemen‑
tioned genes were indicated to be methylated to different extents 
in prostate tissues from patients with PCa. On the contrary, 9 
genes, including Von Hippel‑Lindau tumor suppressor (VHL), 
FOXP1, FOXP2, APC2, ZIC4, phospholipase C like 2 (PLCL2), 
HIC1, ubiquitin conjugating enzyme E2 (UBE2E2) and MGMT 
were identified to be methylated in control and cancer groups. A 
statistically significant difference was indicated in the methyla‑
tion status of the following 13 genes: WNT7A, LRRC3B, FOXP1, 
FOXP3, FOXP4, APC2, ZIC4, CDH1, HOXA9, NDRG4, PTEN, 
MGMT and HIC1. All these genes, except HIC1, had a methyla‑
tion frequency between 0‑12% in the control samples, while in 
the PCa samples methylation frequency was between 13‑58%. 
The HIC1 gene demonstrated a notable methylation frequency 
even in control samples (~39%) and for this reason HIC1 was 
excluded in subsequent analyses. The difference in methylation 
status of VHL, FOXP2, PLCL2, and UBE2E2 genes was indi‑
cated to be statistically insignificant between cancer and control 
individuals (Table III).
The formation of the 6‑gene diagnostic/prognostic panel based 
on correlation analysis. The correlation between the methylation 
of the considered genes and tumor stage was evaluated using the 
Spearman's rank test. A positive correlation was identified in the 
following 14 genes: VHL, WNT7A, LRRC3B, FOXP1, FOXP3, 
FOXP4, APC2, ZIC4, PLCL2, CDH1, HIC1, NDRG4, PTEN and 
MGMT. The genes FOXP3, FOXP4, NDRG4, PTEN and MGMT 
were excluded from subsequent analyses, due to a weak correla‑
tion with the disease stage. Furthermore, VHL was also excluded 
due to low statistical significance (P>0.05), following Bonferroni 
correction, in addition to a number of genes, including FOXP3, 
FOXP4 and PTEN, indicating a weak correlation. In contrast, 3 
genes, FOXP2, HOXA9 and UBE2E2, indicated negative values 
of correlation coefficient. However, they were also rejected due to 
the low correlation with tumor stage.
Table I. Clinical characteristics of patients.
 PCa,  Control,
Variables n=31 (%) n=33
Age, years
  Median 66 62
  Range 29‑82 37‑88
Tumor stage (TNM classification)
  T1 5 (16) ‑
  T2N0M0/NxM0 9 (29) ‑
  T3N0M0 10 (32) ‑
  T2NxM1/N1M1 3 (10) ‑
  T3N1M1 4 (13) ‑
PSA
  Median 37.7 2.0
  Range 5.9‑223.0 0.2‑4.1
Gleason score
  6 10 (32) ‑
  7  11 (36) ‑
  8 3 (10) ‑
  9 2 (6) ‑
  9 5 (16) ‑
  Unknown 5 (16) ‑
‑, not applicable; PCa, prostate cancer; PSA, prostate‑specific antigen; 
T, tumor; N, node; M, metastasis. 
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Table II. Primers used for methylation‑specific polymerase chain reaction. 
Genes Forward 5'‑3' Reverse 5'‑3' Product size (bp)
APC2 
  M ATTTCGGGTCGGGATTTTC GCTTACGTACAACTAAACTAACG 135
  U GTTGTTTGTATTTGTTTGTTTTTGA AAACATAACCTTAAACTCCCCACT 136
CDH1 
  M GGTTTTGACGTCGAGAGTTATAC TACGTAAATTCCAAAAAATATCGTT 211
  U TTTGGTTTTGATGTTGAGAGTTATATG TACATAAATTCCAAAAAATATCATT 214
FOXP1 
  M CGGAGTTCGGAAAATTTAAATACGT GTCTCGAAAAAACGAAAACCGA 87
  U TGGAGTTTGGAAAATTTAAATATGT TCATCTCAAAAAAACAAAAACCAAA 89
FOXP2 
  M CGTTTTTTCGAGGAGAGGTAGTTTC GCGCGCGTATTATTAACAATACG 101
  U TGTTTTTTTGAGGAGAGGTAGTTTT ACACACATATTATTAACAATACAAA 103
FOXP3 
  M GGATAGGGTAGTTAGTTTTCGGAAC GAATACGCCGAACTTCATCGA 93
  U ATAGGGTAGTTAGTTTTTGGAATGA ACCAAATACACCAAACTTCATCAAC 94
FOXP4 
  M TTCGTAGTTATTCGTAGTTTAGGTTTAGTC TCGCGAACTAAAAACTCCGT 120
  U TTGTAGTTATTTGTAGTTTAGGTTTAGTTG TCCTCACAAACTAAAAACTCCATCC 122
HIC1 
  M TTTTATTAGTAATTTAATTCGAATAGCGTC  AACCGCAATCCTAAAAATCG  138
  U TATTAGTAATTTAATTTGAATAGTGTTGG TACAAAACCACAATCCTAAAAATCAC 140
HOXA9 
  M ATCACCTAATAAATTAACCGACG TCGGATTATTAATAGCGTGC 101
  U TGTAGTTTTTAGTTTAAGGTGATGG AATAATAATAATACACCACAACAAA 100
LRRC3B 
  M GGTGCGAGGAAGGTAGGC ACCAATACCTCGCCGACG 222
  U TGGTGTAAGGTAAGGTGTAGTTGT AAACAAAAACAAAAAAAATCAAC 217
MGMT 
  M CGTTTGTAGTTGAGTAAGTATGAGTTTAG AAACGACCCTAAATTCATCGAAAA 263
  U GTTTTGGATATGTTGGGATAGTTTG ACACCTAAAAAACACTTAAAACACA 261
NDRG4 
  M GGTATTTTAGTCGCGTAGAAGGC GTACCCGCGTAAATTTAACGAA 119
  U GTTAGATAGGTGGGTTTTGTAGATG CAAATCAAAACTAAAACAAAAACAC 120
PLCL2 
  M GTATTTTTTTTCGGGAGAGTAAGTC CCAAAAACGACTAAAAATAAACGAT 105
  U TTTTTTTGGGAGAGTAAGTTGG CCAAAAACAACTAAAAATAAACAAT 100
PTEN 
  M TTTTTTTATTTCGTTGTCGTCGT TTAACGATAACTAATACCCCTCGC 155
  U TTTTTTTTATTTTGTTGTTGTTGT TTAACAATAACTAATACCCCTCACT 156
UBE2E2 
  M ATTAGACGGTTCGTAGGGGATATTTC ATATCCGTACAAATCGCAAACTCGA 180
  U GAGATTGAGATTATGGTGAAATTTT ACCCAAACTAAAATACAATAACACA 181
VHL 
  M TTATTCGGGAGGTTGAGGCGAGAC CGCAAAAAAATCCTCCAACACCGTAA 103
  U AGGTAGGATATATTTAGGGTGATGT ACTCCAACCTAAACAACAAAACAA 105
WNT7A 
  M CGAAACCGTCTATCGATACG GTAGTTCGGCGTCGTTTTAC 179
  U TTTTTTGATGTATATTAGGTTTGT CTAAACCACACTACCACAATTTCAA 178
ZIC4 
  M GTTGTAGCGATAAGGTAGGAGTTTC CCACTTTAACGAAATAAAAATCGAT  202
  U TGTAGTGATAAGGTAGGAGTTTTGG CCACTTTAACAAAATAAAAATCAAT 200
M, methylated; U, unmethylated.
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Since PCa is a relatively slow‑growing cancer, the 
actual age‑associated methylation status dynamics may be 
misinterpreted as the respective alterations caused by tumor 
progression (6). Therefore, the correlation between patient's age 
with methylation of the gene panel investigated was also assessed 
(Table III). In the control group, 8/17 genes indicated no corre‑
lation with age (WNT7A, LRRC3B, FOXP3, FOXP4, CDH1, 
HOXA9, NDRG4 and PTEN), 8 demonstrated weak correla‑
tion (VHL, FOXP1, FOXP2, APC2, ZIC4, HIC1, UBE2E2 and 
MGMT) and 1 exhibited moderate correlation (PLCL2). In the 
cancer group all genes were indicated to be weakly correlated 
with age. All 10 genes that indicated moderate correlation with 
tumor stage (VHL, WNT7A, LRRC3B, FOXP1, FOXP3, FOXP4, 
APC2, ZIC4, CDH1 and HIC1) demonstrated a notably weaker 
correlation with age (Table III).
Subsequently, the genes WNT7A, LRRC3B, FOXP1, APC2, 
ZIC4 and CDH1 were selected to form a panel for PCa diag‑
nosis in urine samples, according to the following four criteria: 
Low methylation frequency in control samples, statistically 
significant increase of methylation frequency in patients with 
PCa, notable correlation with PCa progression, and 0 or weak 
correlation with age.
PCa detection and determination of the tumor stage by 
‘number of genes methylated’ (NGM) approach. For the 
interpretation of the results obtained with the 6‑gene panel, 
the ‘number of genes methylated’ (NGM) value ranging from 
0 to 6 was introduced. With the cut‑off value established at 
2, the panel provided PCa detection with 78% sensitivity and 
100% specificity. In the control group NGM values were 0 for 
24 patients and 1 for 9 patients, while none of them had ≥2 
methylated genes (Table IV). The NGM values of patients 
with PCa were uniformly distributed within the range of 0‑5 
reflecting the tumor stage. The mean NGM value determined 
Table III. Methylation status of 17 genes determined in urine. 
 Methylation frequency, % Age correlation (R‑value)
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ Stage correlation for
Genes Control  PCa U‑test (P‑value) Control PCa PCa group (R‑value)
APC2a 12.12 35.48 0.03a 0.21 0.23 0.32b
CDH1a 0.00 48.39 <0.01a 0.00 0.24 0.63b
FOXP1a 9.09 58.06 <0.01a 0.22 ‑0.20 0.41b
FOXP2 3.03 6.45 0.81 0.04 0.07 ‑0.05
FOXP3 0.00 32.26 0.03a 0.00 ‑0.13 0.03
FOXP4 0.00 12.90 0.03a 0.00 ‑0.24 0.16
HIC1 39.39 90.32 <0.01a 0.06 ‑0.10 0.47b
HOXA9 0.00 35.48 <0.01a 0.00 ‑0.09 ‑0.01
LRRC3Ba 0.00 19.35 0.01a 0.00 ‑0.06 0.31b
MGMT 3.03 38.71 <0.01a ‑0.20 ‑0.18 0.01
NDRG4 0.00 32.26 <0.01a 0.00 0.12 0.20
PLCL2  24.24 38.71 0.22 0.36b ‑0.18 0.22
PTEN 0.00 22.58 <0.01a 0.00 0.06 0.05
UBE2E2 3.03 9.68 0.28 0.18 0.11 ‑0.20
VHL 6.06 22.58 0.06 ‑0.30b 0.23 0.37b
WNT7Aa 0.00 41.94 <0.01a 0.00 0.14 0.50b
ZIC4a 6.06 58.06 <0.01a ‑0.08 0.22 0.41b
aSelected genes for panel. PCa. prostate cancer. aStatistical significance. bMild or strong correlation; APC2, adenomatosis polyposis coli 2; 
CDH1, cadherin 1; FOXP1, forkhead box P1; HIC1, hypermethylated in cancer 1; HOXA9, homeobox A9; LRRC3B, leucine rich repeat 
containing 3B; MGMT, O‑6‑methylguanine‑DNA methyltransferase; NDRG4, N‑Myc downstream‑regulated gene 4 protein; PLCL2, phos‑
pholipase C like 2; PTEN, phosphatase and tensin homolog; UBE2E2, ubiquitin conjugating enzyme E2 E2; VHL, Von Hippel‑Lindau tumor 
suppressor; WNT7A, Wnt family member 7A; ZIC4, zinc finger protein of the cerebellum 4.













PCa, prostate cancer; ‑, not applicable. 
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for each PCa stage group (NGMaver) was indicated to almost 
monotonously rise from 0.27‑4.25 along with tumor progres‑
sion and/or increase of its metastatic potential (Fig. 1). In 
particular, in the group with the least developed T1 stage 
cancer the NGM values overlapped with those in controls 
(0‑1); however, it included more NGM 1 values, reaching 
40% of the total number (Table V). Among the patients with 
non‑metastatic PCa of T2/T3 stages, 15/19 patients indicated 
NGM values between 2‑4, while only 4 patients had NGM 
values between 0‑1, as indicated in the control and T1 groups. 
Furthermore, none of the patients with metastatic cancer of 
T2/T3 stages demonstrated an NGM value <4, and in a number 
of cases an NGM value of 5 was reached.
The NGM approach was further tested for its prognostic 
potential. Although the resolving power of this method was 
not adequate to discriminate between all 5 PCa and 1 control 
groups, it provided the discrimination between at least three 
categories of cases: controls and early cancer (T1), developed 
cancer without metastases (T2N0M0/NxM0 and T3N0M0) and 
developed metastatic PCa (T2NxM1/N1M1 and T3N1M1) (Fig. 1). 
The NGMaver of the control and T1 groups was 0.27±0.07 
and 0.40±0.24, respectively, with no significant difference 
between the two groups, but with significant differences 
determined between neighboring groups without metastases, 
T2N0M0/NxM0 and T3N0M0, (P=0.02 and P=0.0009 between 
T1/T2 and T1/T3 groups, respectively). The latter groups also 
demonstrated an NGMaver of 2.10±0.35 and 2.90±0.34, respec‑
tively, and could have not been statistically separated from each 
other, but differed from metastatic groups T2NxM1/N1M1 and 
T3N1M1 (P=0.0009 and P=0.001 comparing non‑metastatic 
T2 and respective groups with metastases; P=0.01 and P=0.02 
comparing non‑metastatic T3 and the respective groups 
with metastases). Finally, the patients with invasive cancer 
T2NxM1/N1M1 and T3N1M1 exhibited NGMaver of 4.60±0.33 
and 4.25±0.25, respectively, and exhibited no statistically 
significant difference between each other. Collectively, these 
data indicated that NGM value could be used to discriminate 
between PCa of three types: Early T1 cancer; T2/T3 cancer 
without metastases; and the highly invasive metastatic T2/T3 
cancer stages.
Discussion
The present study identified 13 tumor suppressor genes under‑
going aberrant methylation in prostate cancer, where 4 of these 
genes have no prior reported association with PCa pathogen‑
esis (24‑26). Furthermore, the present study proposes the 
diagnostic and prognostic panel of 6 genes, which may be used 
for non‑invasive PCa detection and prognosis by non‑invasive 
UcfDNA analysis.
Additionally, the correspondence of polymerase chain 
reaction data obtained from tissue samples and urine was 
examined. Despite the fact that the present study did not 
question the reliability of MSP analysis conducted on urine 
samples without examining the tumor per se, previous afore‑
mentioned advanced techniques made it possible to detect 
methylation events in urine, regardless of apparent UcfDNA 
fragmentation and its comparatively low amount (20). In a 
similar investigation, including the parallel examination of 
PCa tumor samples, it was demonstrated that a positive signal 
for a specific biomarker could be registered from urine in 
Table V. The number of genes methylated values in patients with different stages of prostate cancer.
 T1 T2N0M0/NxM0 T3N0M0 T2NxM1/N1M1 T3N1M1
Panel genes ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
methylated Samples. n % Samples. n % Samples. n % Samples. n % Samples. n %
0 3 60 ‑ ‑ ‑ ‑ ‑ ‑ ‑ ‑
1 2 40 3 33 1 10 ‑ ‑ ‑ ‑
2 ‑ ‑ 3 33 3 30 ‑ ‑ ‑ ‑
3 ‑ ‑ 2 22 2 20 ‑ ‑ ‑ ‑
4 ‑ ‑ 1 12 4 40 1 33 3 75
5 ‑ ‑ ‑ ‑ ‑ ‑ 2 67 1 25
6 ‑ ‑ ‑ ‑ ‑ ‑ ‑ ‑ ‑ ‑
Total 5  9  10  3  4 
‑, not applicable; T, tumor; N, node; M, metastasis according to TNM staging system.
Figure 1. The dependence of NGM value on PCa tumor progression and 
metastasis development. The metastatic groups are marked with grid filling. 
NGM, number of genes methylated; PCa, prostate cancer; T, tumor; N, node; 
M, metastasis; NGMaver, average NGM. 
*P<0.05.
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85% of cases compared with the solid tissue samples (21). 
Furthermore, the urine was indicated to be the most amenable 
source of UcfDNA for cancer detection if compared with other 
types of bodily fluids, including blood and semen (21).
Novel genes associated with PCa were examined and 
the data of the present study indicated that the genes APC2, 
HOXA9, WNT7A and NDRG4 are associated with PCa 
pathogenesis. To the best of our knowledge, this has never 
been demonstrated on a DNA sequence alteration level or in 
epigenetic events. No methylation was indicated in HOXA9, 
WNT7A and NDRG4 genes in any of the control samples, 
while APC2 was methylated in 12% of the control samples. 
In the PCa samples methylation frequencies of aforemen‑
tioned genes reached 35, 42, 32 and 35%, respectively. It 
should be noted that the actual methylation rate of these 
genes in PCa may be even higher when determined in the 
tumor samples themselves, due to seemingly increased 
DNA integrity and amount in solid tissue, compared with 
the UcfDNA pool (17). Further detailed investigation is 
required to clarify the significance of these genes for PCa 
pathogenesis.
Therefore, the present study proposed a 6‑gene panel 
consisting of APC2, CDH1, FOXP1, LRRC3B, WNT7A 
and ZIC4 allowing PCa detection with 78% sensitivity and 
100% specificity. In a number of previous studies, other 
individual genes or their respective panels were considered 
as candidate PCa biomarkers for urine‑based polymerase 
chain reaction diagnostics (20‑21,33‑35). In the present study, 
promoter hypermethylation in the GSTP1 gene, the most 
frequent molecular event in PCa pathogenesis occurring 
in 80‑90% of its cases, was detected in only 27% of urine 
samples, while the respective biopsy samples indicated meth‑
ylation frequency of 79%, which is consistent with previous 
reports (12,20). Although the sensitivity of this test appeared 
to be inadequate for clinical application, it demonstrated the 
practical feasibility of urine polymerase chain reaction/MSP 
examination for PCa diagnosis (20). In another study, it was 
reported that the detection rate in UcfDNA analysis may be 
increased notably by selecting more appropriate experimental 
conditions: When using a DNA isolation kit developed for 
blood/tissue samples, the study reported GSTP1 promoter 
hypermethylation in only 36% of urine samples from patients 
with PCa, but switching to a viral kit allowed the detection 
of this molecular event in 76% of cases investigated (21). 
Furthermore, the use of differential display code 3 (DD3PCA3), 
a gene expressing a non‑coding RNA highly specific for 
prostate tissue, was proposed as a non‑invasive PCa detection 
method. The diagnostic test based on the quantitative deter‑
mination of its transcripts in urine was reported to exhibit 
67% sensitivity and a 90% negative predictive value (33). In 
another study, the use of the p16, p14ARF, MGMT and GSTP1 
gene combination, instead of focusing on a single gene, 
provided a diagnostic test with 87% sensitivity along with 
100% specificity (34). Additionally, a gene panel consisting of 
GSTP1, Ras association domain family member 1A, retinoic 
acid receptor β 2 and APC1 was proposed for detection of 
localized PCa, yielding a sensitivity and accuracy of 86 and 
89%, respectively (35).
The main advantage of the 6‑gene panel proposed in the 
present study over the aforementioned is the prognostic value 
it may bear, as the tumor stage could be at least roughly deter‑
mined based on a NGM value between 0‑6. NGMaver values 
calculated in the cohort rose monotonically from the control 
group, 0.27, to groups with T2 and T3 metastatic cancer types, 
4.6 and 4.25, respectively. This indicated an increased prob‑
ability of identifying malignant and metastatic tumor types 
in a patient with an increased individual NGM value. The 
number of genes included in this 6‑gene panel is increased, 
compared with the 4‑gene panels proposed by Hoque et al (34) 
and Roupret et al (35), which indicates a disadvantage in terms 
of cost‑efficiency; however, it is necessary for distinguishing 
between PCa cases of different stages and metastatic potential. 
It is also important that a 6‑gene set is amenable so that it can 
be applied in a single‑tube multiplex polymerase chain reaction 
screen, providing maximal cost‑efficiency and convenience. 
The cut‑off NGM value of 2 was selected as a diagnostic 
criterion of PCa, since the NGM values of individuals without 
a diagnosed prostate malignancy and T1 cancer extensively 
overlapped in the range of 0‑1. The aforementioned disadvan‑
tage is mitigated by the fact that prostate cancer at T1 stage is 
usually a small localized slow‑growing tumor frequently left 
untreated, due to its asymptomatic nature, and the additional 
age‑associated health problems that the patient with PCa may 
exhibit.
The main limitation of the present study is the relatively 
small patient cohort, including 31 individuals with PCa, while 
other studies of this type usually involve a broader cohort of 
patients, including 67 PCa cases in the study by Salvi et al (22), 
and 52 cases in the study by Hoque et al (34). Nevertheless, 
the number of patients involved in the present study allowed 
the identification of methylation for 13 genes in PCa, and the 
establishment of the correlation with tumor stage for 8 of them 
with adequate statistical significance. Therefore, although the 
6‑gene panel proposed in the present study may not be yet 
applicable in a clinical setting, it could still be potentially used 
for this purpose following additional verification. Furthermore, 
separate genes from the selected panel, whose methylation 
frequency, according to the present data, was increased in 
the PCa group, compared with controls, could be introduced 
in other detecting or prognostic panels. The same applies for 
the comparison of cancer subgroups with different PCa stages 
using the NGM value parameter. Although the NGM value 
tends to rise with tumor development, the application of this 
tool for clinical use requires more precise determination of 
the correspondence between its particular values and the PCa 
stage.
Furthermore, the prognostic potential of the NGM 
approach has its own limitations. Clinical conclusions drawn 
can only be of a probabilistic nature, according to the present 
data, as NGM values obtained from patients with close PCa 
stages partially overlapped. However, at more distant tumor 
stages, NGM values significantly differed, including 0‑1 at 
T1 and 4‑5 at late metastatic stages. Therefore, it was demon‑
strated that the NGM approach serves as a valuable tool for 
further development of the panel proposed here or other gene 
panels designed for PCa prognosis.
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